Literature DB >> 22196453

An analysis of outcomes after use of the Maxwell-Brancheau Arthroereisis implant.

Steven P Brancheau1, Kelly M Walker, David R Northcutt.   

Abstract

The authors present a retrospective study of 35 consecutive patients (60 feet) treated with the Maxwell-Brancheau Arthroereisis (MBA) implant. The mean age of the cohort at the time of surgery was 14.3 (range 5 to 46) years, and 22 (62.86%) men and 13 (37.14%) women were included. Preoperative and postoperative anteroposterior and lateral foot radiographs were compared at a mean of 36 (range 18 to 48) months postoperatively, and the following mean changes were reported: talocalcaneal angle 24.15° ± 7.97° to 18.53° ± 8.23°, calcaneocuboid angle 18.67° ± 8.72° to 11.76° ± 8.49°, first to second intermetatarsal angle 9.42° ± 2.67° to 7.61° ± 2.69°, calcaneal inclination angle 11.93° ± 6° to 14.93° ± 5.85°, and talar declination angle 34.0° ± 8.59° to 28.02° ± 6.85°; all of these differences were statistically significant (p < .0001). A subgroup of 24 (68.57%) patients also answered a subjective questionnaire at a mean of 33 (range 12 to 55) months postoperatively. The presenting chief complaints were resolved in 23 patients (95.83%) of the subgroup, and 21 patients (87.5%) returned postoperatively to either the same or a greater activity level in sports. Twenty-three (95.83% of the subgroup) patients said they were 75% to 100% satisfied with their surgical outcome, and that they would recommend the surgery to a friend or family member with the same condition, whereas 1 (4.17%) claimed 0% satisfaction after placement of inappropriately sized implants (which were later replaced to the patient's clinical satisfaction) in both feet.
Copyright © 2012 American College of Foot and Ankle Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22196453     DOI: 10.1053/j.jfas.2011.10.019

Source DB:  PubMed          Journal:  J Foot Ankle Surg        ISSN: 1067-2516            Impact factor:   1.286


  8 in total

1.  Therapeutic Outcomes of Kalix II in Treating Juvenile Flexible Flatfoot.

Authors:  Le Cao; Xu-Dong Miao; Yong-Ping Wu; Xiang-Feng Zhang; Qiang Zhang
Journal:  Orthop Surg       Date:  2017-02       Impact factor: 2.071

2.  Subtalar extra-articular screw arthroereisis (SESA) for the treatment of flexible flatfoot in children.

Authors:  Maurizio De Pellegrin; Désirée Moharamzadeh; Walter Michael Strobl; Rainer Biedermann; Christian Tschauner; Thomas Wirth
Journal:  J Child Orthop       Date:  2014-11-21       Impact factor: 1.548

3.  Imaging findings of arthroereisis in planovalgus feet.

Authors:  Mika T Nevalainen; Johannes B Roedl; Adam C Zoga; William B Morrison
Journal:  Radiol Case Rep       Date:  2016-09-22

4.  Effectiveness of surgically treated symptomatic plano-valgus deformity by the calcaneo stop procedure according to radiological, functional and gait parameters.

Authors:  Sakti P Das; Pulin B Das; Ganesh S; Mahesh C Sahu
Journal:  J Taibah Univ Med Sci       Date:  2017-01-13

5.  Mid-term Results of Subtalar Arthroereisis with Talar-Fit Implant in Pediatric Flexible Flatfoot and Identifying the Effects of Adjunctive Procedures and Risk Factors for Sinus Tarsi Pain.

Authors:  Sen Wang; Li Chen; Jian Yu; Chao Zhang; Jia-Zhang Huang; Xu Wang; Xin Ma
Journal:  Orthop Surg       Date:  2020-12-17       Impact factor: 2.071

6.  Symptomatic flexible flatfoot in adults: subtalar arthroereisis.

Authors:  Fırat Ozan; Fatih Doğar; Kürşat Gençer; Şemmi Koyuncu; Fatih Vatansever; Fuat Duygulu; Taşkın Altay
Journal:  Ther Clin Risk Manag       Date:  2015-10-16       Impact factor: 2.423

Review 7.  The role of arthroereisis of the subtalar joint for flatfoot in children and adults.

Authors:  Alessio Bernasconi; François Lintz; Francesco Sadile
Journal:  EFORT Open Rev       Date:  2017-11-08

8.  The effect of extra-osseous talotarsal stabilization (EOTTS) to reduce medial knee compartment forces - An in vivo study.

Authors:  Lukas Kolodziej; Rodney K Summers; Michael E Graham
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.